InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
T+90 hit rate
50%
T+90 mean return
-15.6%
Across 8 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by HANNAH ALISON L., Director. Officer active across 4 companies, notably Neogenomics INC. Cumulatively, 14 disclosures have been recorded. History available since 19 May 2021. The latest transaction was disclosed on 1 June 2025 (Levée d'options). Regulator: SEC (Form 4). All data is free.
Declarations14 total
12,254 shares0Common StockSEC:0001077183-25-000132
12,254 shares0Common StockSEC:0001077183-25-000132:0
11,336 shares0Common StockSEC:0001077183-24-000127:0
25,000 shares0Common StockSEC:0000905148-24-001652:0
25,000 shares0Common StockSEC:0001140361-23-034282:0
15,000 shares0Common StockSEC:0001567619-22-014297:0
15,556 shares0Common StockSEC:0001077183-22-000110:0
25,000 shares0Common StockSEC:0001140361-22-020304:0
22,500 shares0Common StockSEC:0001567619-22-002523
22,500 shares0Common StockSEC:0001567619-22-002523:0
3,081 shares0Common StockSEC:0001077183-21-000162:0
3,081 shares0Common StockSEC:0001077183-21-000162
6,250 shares0Common StockSEC:0001179110-21-005772
6,250 shares0Common StockSEC:0001179110-21-005772:0
14 of 14 declarations
About HANNAH ALISON L.
Alison L. Hannah is a Board Member and Chief Medical Officer at NEOGENOMICS INC and RIGEL PHARMACEUTICALS INC. She oversees medical affairs and contributes to the company's strategy. Hannah plays a key role in innovation and the development of new treatments.
